These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16110693)

  • 1. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of double-dose transdermal scopolamine.
    Bar R; Gil A; Tal D
    Pharmacotherapy; 2009 Sep; 29(9):1082-8. PubMed ID: 19698013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study.
    Gil A; Nachum Z; Tal D; Shupak A
    Clin Neuropharmacol; 2012; 35(1):37-9. PubMed ID: 22139622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
    Attias J; Gordon C; Ribak J; Binah O; Rolnick A
    Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Republic of Singapore Navy's Scopoderm TTS study: results after 2,200 man-days at sea.
    How J; Lee PS; Seet LC; Tan PK
    Aviat Space Environ Med; 1988 Jul; 59(7):646-50. PubMed ID: 3044323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness.
    Pingree BJ; Pethybridge RJ
    Aviat Space Environ Med; 1994 Jul; 65(7):597-605. PubMed ID: 7945125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transderm scopolamine efficacy related to time of application prior to the onset of motion.
    Levy GD; Rapaport MH
    Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S; Shapira S; Zilbiger A; Ribak J
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scopolamine: new preparations. Reference treatment for death rattle.
    Prescrire Int; 2001 Aug; 10(54):99-101. PubMed ID: 11718188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.
    Renner UD; Oertel R; Kirch W
    Ther Drug Monit; 2005 Oct; 27(5):655-65. PubMed ID: 16175141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal scopolamine use for post-rhytidectomy sialocele.
    Lapid O; Kreiger Y; Sagi A
    Aesthetic Plast Surg; 2004; 28(1):24-8. PubMed ID: 15116278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET; Zhou DR; He LH
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of drooling using transdermal scopolamine skin patches. A case report.
    Mato Montero A; Limeres Posse J; Tomás Carmona I; Fernández Feijoo J; Diz Dios P
    Med Oral Patol Oral Cir Bucal; 2008 Jan; 13(1):E27-30. PubMed ID: 18167476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Airsickness prevention in helicopter passengers.
    Estrada A; LeDuc PA; Curry IP; Phelps SE; Fuller DR
    Aviat Space Environ Med; 2007 Apr; 78(4):408-13. PubMed ID: 17484344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.